European Journal of Heart Failure Publishes Pre
... (Angiotensin-Converting-Enzyme) inhibitors. Although RAAS inhibition has been shown to protect kidney and cardiac function, many patients who could benefit from RAAS inhibitors are untreated or undertreated due to these medicines having an undesirable side effect of increasing blood potassium. About ...
... (Angiotensin-Converting-Enzyme) inhibitors. Although RAAS inhibition has been shown to protect kidney and cardiac function, many patients who could benefit from RAAS inhibitors are untreated or undertreated due to these medicines having an undesirable side effect of increasing blood potassium. About ...
Posttraumatic Stress Disorder and Military Veterans
... Dr. Shapiro conducted a controlled study where randomly assigned 22 individuals with traumatic memories to two conditions: half received EMD and half received the same therapeutic procedure with imagery and detailed description replacing the eye movement. Report showed that EMD resulted in significa ...
... Dr. Shapiro conducted a controlled study where randomly assigned 22 individuals with traumatic memories to two conditions: half received EMD and half received the same therapeutic procedure with imagery and detailed description replacing the eye movement. Report showed that EMD resulted in significa ...
June 2015 Monitoring International Trends
... of the first patient with severe sickle cell disease (SCD) treated with the company’s LentiGlobin BB305. It regards the data as promising. The proportion of anti-sickling haemoglobin being produced by this patient treated with gene therapy is rising steadily and accounted for 45 per cent of all haem ...
... of the first patient with severe sickle cell disease (SCD) treated with the company’s LentiGlobin BB305. It regards the data as promising. The proportion of anti-sickling haemoglobin being produced by this patient treated with gene therapy is rising steadily and accounted for 45 per cent of all haem ...
ATOPICA 10 mg soft capsules for dogs
... Interaction with other medicinal products and other forms of interaction Various substances are known to competitively inhibit or induce the enzymes involved in the metabolism of ciclosporin, in particular cytochrome P450 (CYP 3A 4). In certain clinically justified cases, an adjustment of the dosage ...
... Interaction with other medicinal products and other forms of interaction Various substances are known to competitively inhibit or induce the enzymes involved in the metabolism of ciclosporin, in particular cytochrome P450 (CYP 3A 4). In certain clinically justified cases, an adjustment of the dosage ...
Advances in the Management of Gastroesophageal
... controlling symptoms.30 In contrast, omeprazole demonstrated a dose-response relationship, in which 20 mg/day provided significantly better endoscopic healing and symptomatic relief than 10 mg/day.31 PPIs are well tolerated by most patients and are associated with minimal side effects, but several c ...
... controlling symptoms.30 In contrast, omeprazole demonstrated a dose-response relationship, in which 20 mg/day provided significantly better endoscopic healing and symptomatic relief than 10 mg/day.31 PPIs are well tolerated by most patients and are associated with minimal side effects, but several c ...
Salmeterol vs. Combination Therapy
... A total of 15 studies of good methodological quality met the inclusion criteria by randomly assigning 7814 participants with predominantly poorly reversible, severe COPD. Data were most plentiful for the FPS combination. Exacerbation rates were significantly reduced with combination therapies (rate ...
... A total of 15 studies of good methodological quality met the inclusion criteria by randomly assigning 7814 participants with predominantly poorly reversible, severe COPD. Data were most plentiful for the FPS combination. Exacerbation rates were significantly reduced with combination therapies (rate ...
ANTIPSYCHOTICS
... 3) Fasting plasma glucose level or hemoglobin A1c – before initiating a new antipsychotic, then yearly. If a patient has significant risk factors for diabetes and for those that are gaining weight – before initiating a new antipsychotic, 4 months after starting an antipsychotic, and then yearly. 4) ...
... 3) Fasting plasma glucose level or hemoglobin A1c – before initiating a new antipsychotic, then yearly. If a patient has significant risk factors for diabetes and for those that are gaining weight – before initiating a new antipsychotic, 4 months after starting an antipsychotic, and then yearly. 4) ...
Clinical mathematics review - College of Health Professions
... vecuronium 7 mg, rocuronium 42 mg, cis-atracurium 14 mg, and pancuronium 7 mg. (Of course you would modify these doses based on body habitus and past history.) Remember "same as…" doses. For example, vecuronium and pancuronium. Or similar doses like the pair esmolol (bolus 0.5 mg/kg) and rocuronium ...
... vecuronium 7 mg, rocuronium 42 mg, cis-atracurium 14 mg, and pancuronium 7 mg. (Of course you would modify these doses based on body habitus and past history.) Remember "same as…" doses. For example, vecuronium and pancuronium. Or similar doses like the pair esmolol (bolus 0.5 mg/kg) and rocuronium ...
Medication Assisted Treatment in Adolescents
... Niederhofer, H. and W. Staffen (2003). "Acamprosate and its efficacy in treating alcohol dependent adolescents." Eur Child Adolesc Psychiatry 12(3): 144-148. Niederhofer, H. and W. Staffen (2003). "Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents." Drug Alco ...
... Niederhofer, H. and W. Staffen (2003). "Acamprosate and its efficacy in treating alcohol dependent adolescents." Eur Child Adolesc Psychiatry 12(3): 144-148. Niederhofer, H. and W. Staffen (2003). "Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents." Drug Alco ...
NDA 201277 Gadavist FDA Approved 27 Apr 2016 See full
... of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The adverse reactions described in this section reflect Gadavist exposure in 6,809 subjects (including 184 pediatric patients, ages 0 to 17 years) with t ...
... of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The adverse reactions described in this section reflect Gadavist exposure in 6,809 subjects (including 184 pediatric patients, ages 0 to 17 years) with t ...
Zometa - Medsafe
... rabbits. It was found to be teratogenic at doses 0.2 mg/kg bodyweight in rats. In rabbits, there was no teratogenicity or foeto-toxicity but maternotoxicity was found. Zometa should not be used during pregnancy (see Contraindications). Breast-feeding It is not known whether zoledronic acid is excre ...
... rabbits. It was found to be teratogenic at doses 0.2 mg/kg bodyweight in rats. In rabbits, there was no teratogenicity or foeto-toxicity but maternotoxicity was found. Zometa should not be used during pregnancy (see Contraindications). Breast-feeding It is not known whether zoledronic acid is excre ...
A case for psilocybin
... (JHU) and New York University (NYU) were methodologically rigorous and broad in the scope of their outcome variables. Both studies demonstrated that a single-dose of psilocybin can produce both an acute and enduring reduction in depression symptoms, anxiety, and existential distress in patients with ...
... (JHU) and New York University (NYU) were methodologically rigorous and broad in the scope of their outcome variables. Both studies demonstrated that a single-dose of psilocybin can produce both an acute and enduring reduction in depression symptoms, anxiety, and existential distress in patients with ...
Calculating equivalent doses of oral benzodiazepines
... dose. It is necessary to take the tablets several times a day and many people experience a "mini-withdrawal", sometimes a craving, between each dose. For people withdrawing from these potent, short-acting drugs it has been advised that they switch to an equivalent dose of a benzodiazepine with a lon ...
... dose. It is necessary to take the tablets several times a day and many people experience a "mini-withdrawal", sometimes a craving, between each dose. For people withdrawing from these potent, short-acting drugs it has been advised that they switch to an equivalent dose of a benzodiazepine with a lon ...
Assessing the Evidence: What Science Has To Say About the Prescribing
... array of treatment-related adverse events.” Source: R. Findling. “Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrume (TEOSS) study.” J Am Acad Child & Adolesc Psychiatry 49 (2010): 583-95. J. Jerrell, “Adverse events in children and a ...
... array of treatment-related adverse events.” Source: R. Findling. “Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrume (TEOSS) study.” J Am Acad Child & Adolesc Psychiatry 49 (2010): 583-95. J. Jerrell, “Adverse events in children and a ...
Hypertensive patients with concomitant diseases
... Nitroprusside is administered intravenously and causes prompt vasodilation with reflex tachycardia. It is capable of reducing blood pressure in all patients regardless of the cause of hypertension. The drug has little effect outside the vascular system, acting equally on arterial and venous smooth m ...
... Nitroprusside is administered intravenously and causes prompt vasodilation with reflex tachycardia. It is capable of reducing blood pressure in all patients regardless of the cause of hypertension. The drug has little effect outside the vascular system, acting equally on arterial and venous smooth m ...
Clinical trials - MND Association
... unintentional bias creeping in when participants are reporting how they feel or when researchers are looking at data from the trial. However, a central trial co-ordinating centre does know who is taking the trial drug and can make this information available very quickly if a patient suffers a possib ...
... unintentional bias creeping in when participants are reporting how they feel or when researchers are looking at data from the trial. However, a central trial co-ordinating centre does know who is taking the trial drug and can make this information available very quickly if a patient suffers a possib ...
Antidepressants, Antipsychotics, Antianxiety
... ______________ - _____________________________________________________ ________________- _____________________________________________________ ...
... ______________ - _____________________________________________________ ________________- _____________________________________________________ ...
Beating an addiction to meth
... into small communities in the Midwest. “These rural areas had not been very affected by cocaine or heroin so when they had to start dealing with meth users they had no idea what to do with them,” said Richard Rawson, executive director of the Matrix Institute, a nonprofit addiction research organiza ...
... into small communities in the Midwest. “These rural areas had not been very affected by cocaine or heroin so when they had to start dealing with meth users they had no idea what to do with them,” said Richard Rawson, executive director of the Matrix Institute, a nonprofit addiction research organiza ...
Document
... a. The dosage of heroine (<6 mg/day no or mild symptom) b. The duration of maternal addiction: (<1y 55%, >1y 73% incidence of withdrawal) c. The time of last maternal dose: ↑incidence if drug taken within 24 hrs of birth. ...
... a. The dosage of heroine (<6 mg/day no or mild symptom) b. The duration of maternal addiction: (<1y 55%, >1y 73% incidence of withdrawal) c. The time of last maternal dose: ↑incidence if drug taken within 24 hrs of birth. ...
Opioid conversion tips Changing to another oral opioid
... † Risk of CNS depression with repeated use; accumulation in elderly or persons with impaired renal function with regular dosing. Monitor for patient variability in duration of efficacy. ...
... † Risk of CNS depression with repeated use; accumulation in elderly or persons with impaired renal function with regular dosing. Monitor for patient variability in duration of efficacy. ...
Memory Medications
... o Moderate to severe AD o Vascular dementia o May also help manage aggression/agitation MOA: uncompetitive antagonist at NMDA receptors o Only binds to R when it has already bound glutamate o Therefore, use-dependent blockade of overly active NMDA that pass Ca++ and may lead to excitotoxicity (ie. m ...
... o Moderate to severe AD o Vascular dementia o May also help manage aggression/agitation MOA: uncompetitive antagonist at NMDA receptors o Only binds to R when it has already bound glutamate o Therefore, use-dependent blockade of overly active NMDA that pass Ca++ and may lead to excitotoxicity (ie. m ...
johns hopkins study probes - Council on Spiritual Practices
... These findings reinforce previous Hopkins research showing that psilocybin, given under well-designed conditions, has a high probability of leading to mystical or spiritual experiences descriptively identical to spontaneous ones mystics have reported across cultures and throughout the ages, while no ...
... These findings reinforce previous Hopkins research showing that psilocybin, given under well-designed conditions, has a high probability of leading to mystical or spiritual experiences descriptively identical to spontaneous ones mystics have reported across cultures and throughout the ages, while no ...
Premature Ejaculation
... Acknowledgements and Disclaimers: AUA Guideline on the Management of Premature Ejaculation (PE) This document was written by the Erectile Dysfunction Guideline Update Panel of the American Urological Association Education and Research, Inc., which was created in 1999. The Practice Guidelines Commit ...
... Acknowledgements and Disclaimers: AUA Guideline on the Management of Premature Ejaculation (PE) This document was written by the Erectile Dysfunction Guideline Update Panel of the American Urological Association Education and Research, Inc., which was created in 1999. The Practice Guidelines Commit ...
Renal failure
... but oral CA inhibitor is still often regarded as the most powerful medication for reducing intra-ocular pressure ...
... but oral CA inhibitor is still often regarded as the most powerful medication for reducing intra-ocular pressure ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.